EAST ROCHESTER, N.Y., June 17, 2021 /PRNewswire-PRWeb/ -- CHESS Health, the leading provider of comprehensive addiction technology and support services, announced the addition of virtual recovery support meetings to its leading evidence-based Connections smartphone app.
Search / 248 results found Showing: 1-10 of 248
ALBANY, N.Y., June 17, 2021 /PRNewswire/ -- The world is observing consistent upward curve in the cases of cardiovascular diseases from past many years. In addition to this, there is remarkable growth in the specific fundamental health conditions including apnea or agonal breathing, which are reason for cardiac arrest. Some of the key factors responsible for this scenario include varied lifestyle choices including lack of exercise, a hectic work schedule, and tobacco and alcohol use. Thus, increased cases of cardiovascular diseases are expected to bring extensive sales avenues in the global cardiac arrest treatment market in the years to come.
- Cardiac arrest treatment market is projected to account for US$3900 Mn during analysis period 2019–2027. Increased research activities will help in further driving the market expansion
POUGHKEEPSIE, N.Y., June 17, 2021 /PRNewswire/ -- Dr. Randy Pardell, Medical Director of the TMS Center of Hudson Valley, has been announced President of the Clinical TMS Society. Dr. Pardell's appointment was confirmed at the Clinical TMS Annual Meeting currently being held in West Palm Beach, Florida. He will assume the role of President immediately as the term of the current President, Kimberley Cress, ended over the weekend at the Annual Meeting.
JERUSALEM, June 16, 2021 /PRNewswire/ -- KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced the first closing of an investment round raising $46.5 million. The financing was led by aMoon with participation from new investors BVF Partners LP, DAFNA Capital Management LLC, Peregrine Ventures, Shavit Capital and the Cancer Focus Fund. Existing investors also participated in this financing, including Flerie Invest AB, Oriella Limited (CBG, chaired by Vincent Tchenguiz), Pavilion Capital, Hadasit Bio Holdings Ltd (HBL) and Mirae Asset.
NEW YORK, June 15, 2021 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant and/or allowance of a series of patents and patent applications. These patents and patent applications, which were granted/allowed in 2020 and 2021, are expected to provide broad protection for Brainstorm's proprietary NurOwn® (MSC-NTF cells) technology in territories including the U.S., E.U., Canada, Israel and Hong Kong.
KINGSTON, N.Y., June 15, 2021 /PRNewswire/ -- Child & Family Guidance Center Addiction Services, Inc. d/b/a Step One announced today the grand opening and ribbon-cutting ceremony for their new Step One Kingston location. Step One has gained an excellent reputation for providing quality client centered treatment to Ulster County's adolescent and adult substance using and co-occurring population and their families.
NEW YORK, June 15, 2021 /PRNewswire/ -- As part of its mission to offer people living with Parkinson's and their families with high-quality educational resources on navigating the disease journey, The Michael J. Fox Foundation for Parkinson's Research (MJFF) today launches "Deep Brain Stimulation and Parkinson's — From Decision-making to Daily Life with the Device." The new resource, available at michaeljfox.org/DBSguide, educates patients and care partners about deep brain stimulation (DBS) surgery as a treatment option to help manage symptoms, provides practical tips for thinking about, undergoing and living with DBS, includes perspectives and voices from the patient and family community; and shares the latest research and DBS devices available.
NEW YORK, June 14, 2021 /PRNewswire/ -- Certain patients with an aggressive form of ovarian cancer have a better chance of a cure through surgical removal of their tumor before chemotherapy instead of the reverse, a new study shows.
- AADvac1 demonstrates robust antibody response, excellent safety profile and highly significant impact on neurodegeneration